Sign In
Buy NTLA
$14.75
+1.73 (+13.29%)
At Close: Jun 04, 2026
Is Intellia Therapeutics Stock a Buy Now?
09:45am, Saturday, 09'th Mar 2024
Intellia Therapeutics has two candidates in or close to entering late-stage studies. The company's shares could rise significantly if it records positive trial results.
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
10:35am, Wednesday, 06'th Mar 2024
Intellia Therapeutics is expected to give updates on a pair of programs. The quality of its data will determine how much the market reacts.
Top 3 Wall Street stock picks for March
08:51am, Wednesday, 06'th Mar 2024
While the stock market is not yet free of recessionary fears and remains affected by high interest rates, 2024 has, so far, brought significant positive developments if things are to be judged by majo
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors
10:31am, Wednesday, 28'th Feb 2024
Intellia Therapeutics, Inc. (NTLA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NTLA broke through the 50-day moving average, whi
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11:55am, Tuesday, 27'th Feb 2024
Ark Invest bought shares of Roku, 10x Genomics, and Intellia Therapeutics on Monday. Roku has shed more than one-third of its value over the past two weeks after a series of unfortunate events.
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average
10:36am, Tuesday, 27'th Feb 2024
Intellia Therapeutics, Inc. (NTLA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, NTLA crossed above the 20-day moving avera
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update
12:16pm, Friday, 23'rd Feb 2024
Intellia's (NTLA) earnings beat estimates in the fourth quarter while the company reports negative revenues. Management provides developmental and regulatory updates on its key pipeline candidates.
Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High?
10:56am, Friday, 23'rd Feb 2024
The consensus price target hints at an 185.5% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
10:16am, Wednesday, 21'st Feb 2024
Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
05:02am, Tuesday, 20'th Feb 2024
Cathie Wood's biggest bet in her healthcare fund is on a gene editing company. Gene editing has the potential to offer functional cures for serious diseases, so it could be a gamechanger.
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
04:08pm, Monday, 19'th Feb 2024
Biotech stocks, namely those involved with gene editing, have been explosive. Just look at CRISPR Therapeutics (NASADQ: CRSP ), for example.
Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?
01:59am, Saturday, 17'th Feb 2024
Wall Street analysts have high hopes for Intellia Therapeutics stock. The company's late-stage pipeline programs are shaping up nicely.
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:06am, Thursday, 15'th Feb 2024
Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
06:46am, Thursday, 15'th Feb 2024
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
07:30am, Wednesday, 14'th Feb 2024
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
